Related Articles
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non‑small‑cell lung cancer (Review)
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
Transformation from adenocarcinoma to squamous cell carcinoma associated with long‑term administration of EGFR‑TKIs
EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy